This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Currently, we are actively working on co-packaging collaborations with pharma companies to drive adoption across various medical sectors, including paediatrics, infertility treatments, and broader healthcare applications. billion in 2028, growing at a compound annual growth rate (CAGR) of 14.16 What are the projections?
These new results reinforce our differentiating data package for PDC*lung01. We are very pleased to demonstrate that our innovative immunotherapy platform can induce a strong immune response in humans. We reported at ESMO-IO the analysis of immune response of the first 3 cohorts of patients. 2015; Zhu et al., 2015; Zhu et al.,
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
82 
Let's personalize your content